Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020097513 - METHODS FOR SHRINKING PITUITARY TUMORS

Publication Number WO/2020/097513
Publication Date 14.05.2020
International Application No. PCT/US2019/060548
International Filing Date 08.11.2019
IPC
A61K 31/4745 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61B 17/3205
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
17Surgical instruments, devices or methods, e.g. tourniquets
32Surgical cutting instruments
3205Excision instruments
A61K 31/444
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
A61N 5/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
5Radiation therapy
10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • CORCEPT THERAPEUTICS INCORPORATED [US]/[US]
Inventors
  • MORAITIS, Andreas
Agents
  • GAO, Chuan
  • WEBER, Kenneth A.
  • LOCKYER, Jean M.
  • SHURTZ, Kenneth R.
Priority Data
62/758,47709.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR SHRINKING PITUITARY TUMORS
(FR) MÉTHODES DE RÉDUCTION DES TUMEURS PITUITAIRES
Abstract
(EN)
Pituitary tumors may be reduced in size by administration of relacorilant. Pituitary tumors include, without limitation, non-secreting tumors, hormone-secreting tumors, adenomas, and carcinomas. Relacorilant administration may be effective to reduce hormone secretion from a hormone-secreting pituitary tumor, e.g., to reduce adrenocorticotrophic hormone (ACTH) secretion. A pituitary tumor may be imaged before and/or after relacorilant administration. Relacorilant may be administered independent of surgery, and before, during, or after surgery to treat a pituitary tumor. Relacorilant may aid or improve surgical outcomes, and may reduce the size or growth of pituitary tumor tissue before surgery, and any tumor tissue remaining following surgical treatment. Relacorilant may be orally administered for the treatment of pituitary tumors. Relacorilant may be orally administered to a fasted patient, or to a fed patient. Relacorilant may be administered in conjunction with other pituitary tumor targeting treatments, including surgical treatments, radiation treatments, chemotherapy for carcinomas, and other pharmaceutical treatments.
(FR)
Selon l'invention, la taille de tumeurs pituitaires peut être réduite par l'administration de relacorilant. Les tumeurs pituitaires comprennent, sans limitation, des tumeurs non sécrétrices, des tumeurs sécrétrices d'hormones, des adénomes et des carcinomes. L'administration de relacorilant peut être efficace pour réduire la sécrétion d'hormones à partir d'une tumeur pituitaire sécrétant des hormones, par exemple, pour réduire la sécrétion d'hormone adrénocorticotrophique (ACTH). Une tumeur pituitaire peut être imagée avant et/ou après une administration de relacorilant. Le relacorilant peut être administré indépendamment de la chirurgie, et avant, pendant ou après une chirurgie pour traiter une tumeur pituitaire. Le relacorilant peut aider ou améliorer des résultats chirurgicaux, et peut réduire la taille ou la croissance de tissu tumoral pituitaire avant la chirurgie, et de tout tissu tumoral restant après un traitement chirurgical. Le relacorilant peut être administré par voie orale pour le traitement de tumeurs pituitaires. Le relacorilant peut être administré par voie orale à un patient à jeun, ou à un patient ayant mangé. Le relacorilant peut être administré conjointement avec d'autres traitements de ciblage de tumeur pituitaire, y compris des traitements chirurgicaux, des radiothérapies, une chimiothérapie pour carcinomes, et d'autres traitements pharmaceutiques.
Latest bibliographic data on file with the International Bureau